US-based medical device company Amgen has secured US Food and Drug Administration (FDA) approval for its Repatha (evolocumab) Pushtronex system which is an on-body infusor with prefilled cartridge.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Pushtronex system is a hands-free device which offers a single dose administration of 420mg of Repatha.

Repatha is a human monoclonal antibody acting as a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor.

Amgen research and development executive vice-president Sean Harper said: “The Pushtronex system exemplifies Amgen’s continued innovation and commitment to patients.

“Repatha is the only PCSK9 inhibitor with an approved monthly dose, and now the only one with a monthly single-dose administration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The FDA approval of the Pushtronex system offers another delivery option to patients who need the additional LDL cholesterol lowering that Repatha can provide.”

Developed in cooperation with West Pharmaceutical Services, the new, single-use device operates on the SmartDose technology platform which offers patients with an additional dosing option for Repatha treatment.

“The FDA approval of the Pushtronex system offers another delivery option to patients who need the additional LDL cholesterol lowering that Repatha can provide.”

The SmartDose technology platform also enables self-administration by patients in accordance with their prescribed treatment.

The technology platform was built on extensive human factors testing and analysis to foster the interaction between the patient and the delivery system.

The device adheres to the anatomy and patients are hands free during administration.

The usage of the device does not interfere into the patient’s moderate physical activities such as walking, reaching or bending while subcutaneously delivering 420 mg of Repatha.

Image: Amgen’s Pushtronex system. Photo: courtesy of PRNewsFoto / Amgen.